BR112013018998A2 - composições contendo anticorpos glicosilados e seus usos - Google Patents

composições contendo anticorpos glicosilados e seus usos

Info

Publication number
BR112013018998A2
BR112013018998A2 BR112013018998A BR112013018998A BR112013018998A2 BR 112013018998 A2 BR112013018998 A2 BR 112013018998A2 BR 112013018998 A BR112013018998 A BR 112013018998A BR 112013018998 A BR112013018998 A BR 112013018998A BR 112013018998 A2 BR112013018998 A2 BR 112013018998A2
Authority
BR
Brazil
Prior art keywords
compositions containing
human antibodies
antibody
glycosylated antibodies
antibodies
Prior art date
Application number
BR112013018998A
Other languages
English (en)
Inventor
Ivan R S Correia
Matthew W Hruska
Susan Kaye
Taro Fujimori
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112013018998A2 publication Critical patent/BR112013018998A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

composições contendo anticorpos glicosilados e seus usos a presente invenção provê composições de anticorpos, por exemplo, anticorpos humanos, com graus variados de glicosilação em suas estruturas que servem para alcançar taxas desejadas de depuração sérica. a invenção também provê métodos para modular a farmacocinética de anticorpos humanos, e composições terapêuticas contendo tais anticorpos. estes métodos baseiam-se em variar a glicosilação nas estruturas dos anticorpos, por exemplo, anticorpos humanos, para alcançar taxas de depuração sérica.
BR112013018998A 2011-01-28 2012-01-26 composições contendo anticorpos glicosilados e seus usos BR112013018998A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437107P 2011-01-28 2011-01-28
PCT/US2012/022742 WO2012103345A1 (en) 2011-01-28 2012-01-26 Compositions containing glycosylated antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112013018998A2 true BR112013018998A2 (pt) 2016-08-09

Family

ID=46577528

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018998A BR112013018998A2 (pt) 2011-01-28 2012-01-26 composições contendo anticorpos glicosilados e seus usos

Country Status (15)

Country Link
US (1) US20120195885A1 (pt)
EP (1) EP2668283A1 (pt)
JP (1) JP2014505075A (pt)
KR (1) KR20140114271A (pt)
CN (1) CN103492584A (pt)
AU (1) AU2012211262A1 (pt)
BR (1) BR112013018998A2 (pt)
CA (1) CA2824927A1 (pt)
IL (1) IL227542A0 (pt)
MX (1) MX2013008702A (pt)
RU (1) RU2013139734A (pt)
SG (1) SG192183A1 (pt)
TW (1) TW201309330A (pt)
WO (1) WO2012103345A1 (pt)
ZA (1) ZA201305504B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
JPWO2021140981A1 (pt) * 2020-01-10 2021-07-15

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
AU2004226167A1 (en) * 2003-04-03 2004-10-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies with enhanced ability to immunomodulate cell functions
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2035034A4 (en) * 2006-06-09 2009-11-18 Univ Maryland GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
RU2570633C2 (ru) * 2009-05-27 2015-12-10 Ф.Хоффманн-Ля Рош Аг Три- или тетраспецифические антитела

Also Published As

Publication number Publication date
AU2012211262A1 (en) 2013-08-01
WO2012103345A1 (en) 2012-08-02
KR20140114271A (ko) 2014-09-26
US20120195885A1 (en) 2012-08-02
ZA201305504B (en) 2015-08-26
SG192183A1 (en) 2013-09-30
TW201309330A (zh) 2013-03-01
JP2014505075A (ja) 2014-02-27
CN103492584A (zh) 2014-01-01
CA2824927A1 (en) 2012-08-02
RU2013139734A (ru) 2015-03-10
MX2013008702A (es) 2013-12-06
IL227542A0 (en) 2013-09-30
EP2668283A1 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
BR112013018998A2 (pt) composições contendo anticorpos glicosilados e seus usos
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BR112014030009A2 (pt) polipeptídeos que têm atividade de transgalactosilação
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
CL2015003193A1 (es) Formulaciones de anticuerpos biespecíficos anti-il-4/anti-il-13
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CL2015001314A1 (es) Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).
CL2015001472A1 (es) Composiciones y métodos para anticuerpos dirigidos epo.
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112013021134A8 (pt) Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
BR112015006060A2 (pt) agentes de ligação kir3dl2
BR112015002152A2 (pt) pirróis substituídos ativos como inibidores de quinases
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112012018021A2 (pt) antídotos anticoagulantes.
BR112013026883A2 (pt) Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
BR112016014756A8 (pt) formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
BR112016003293A2 (pt) anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.